BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guo A, Ross C, Chande N, Gregor J, Ponich T, Khanna R, Sey M, Beaton M, Yan B, Kim RB, Wilson A. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists. Sci Rep 2022;12:1185. [PMID: 35075155 DOI: 10.1038/s41598-022-05208-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Bertani L. Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic Choices. JCM 2022;11:5267. [DOI: 10.3390/jcm11185267] [Reference Citation Analysis]
2 Lin S, Chanchlani N, Carbery I, Janjua M, Nice R, McDonald TJ, Bewshea C, Kennedy NA, Ahmad T, Selinger CP, Goodhand JR; PANTS consortium. Understanding anti-TNF treatment failure: Does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease? Aliment Pharmacol Ther 2022. [PMID: 35768996 DOI: 10.1111/apt.17089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]